TrialThe New England journal of medicine2022
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Frederick L Locke et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
921 papers cite itlatest 60 shown
this paperpooled ittrialcites it